Indometacin With or Without Aggressive Intravenous Hydration to Prevent Pancreatitis After Pancreatic Extracorporeal Shock Wave Lithotripsy

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-85
SponsorChanghai Hospital

About this trial

This study aims to determine whether combining aggressive intravenous hydration with indometacin is more effective at preventing pancreatitis after a Extracorporeal Shock Wave Lithotripsy (ESWL) than using indometacin alone.

The study will involve patients who are scheduled to undergo ESWL for pancreatic stones. Participants will be randomly assigned to one of two groups: one will receive both the intravenous hydration and the rectal indometacin, while the other will receive only the rectal indometacin.

The trial will be conducted at multiple centers, ensuring a broad and diverse patient population.

The primary outcome of the study will be the incidence of pancreatitis after the ESWL procedure.

This study is important because it could lead to a better understanding of how to prevent pancreatitis after ESWL, potentially improving patient outcomes and reducing the risk of serious complications.

Eligibility criteria

Qualifiers

Patients with painful chronic pancreatitis eligible for P-ESWL treatment

Ages between 18-85 years

Providing informed consent

Disqualifiers

Patients readmitted to the hospital for ESWL during the study period

contraindications to ESWL

Signs of congestive heart failure, such as pitting edema or a New York Heart Association classification greater than class I heart failure. For patients ≥ 70 years old, brain natriuretic peptide (BNP) and cardiac ultrasound would be performed before ESWL. Patients with BNP>100pg/ml or Ejection Fraction value<50% should be excluded

Respiratory insufficiency (pO2 < 60 mmHg or saturation < 90% despite FiO2 of 30% or requiring mechanical ventilation). For patients ≥ 70 years old, pulmonary function tests would be performed before ESWL. Patients with Forced Expiratory Volume in the first second (FEV1) <70% are excluded

Trial design

Treatments tested in this trial

  • Indometacin suppository
  • Lactated ringers solution
  • Normal Saline

Treatment groups

1,250 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Changhai Hospital

Lead sponsor

Ruijin Hospital

Collaborator

LanZhou University

Collaborator

First People's Hospital of Hangzhou

Collaborator

The Second Affiliated Hospital of Baotou Medical College

Collaborator

Shanghai Pudong New Area Gongli Hospital

Collaborator

Peking Union Medical College Hospital

Collaborator

Qilu Hospital of Shandong University

Collaborator

The Third Xiangya Hospital of Central South University

Collaborator

Affiliated Hospital of Yunnan University

Collaborator